San Francisco General Hospital

Running trials

• Not yet recruiting

  Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center

  NCT07519707· University of California, San Francisco· Source

• Not yet recruiting

  "Discovery2" Study of Using MCG at Emergency Departments

  NCT07822581· SB Technology, Inc.· Source

• Active, not recruiting

  Acceptability of MBSR for People With HS

  NCT07903948· University of California, San Francisco· Source

• Recruiting

  Technology Assisted Motivational Interviewing

  NCT06713603· University of California, San Francisco· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

• Active, not recruiting

  A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

  NCT06891066· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

  NCT06249165· Phase 4· Duke University· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Recruiting

  Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

  NCT05832229· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Recruiting

  Recovery Trajectory for Coma and Disorders of Consciousness

  NCT07614074· University of California, San Francisco· Source

• Recruiting

  Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

  NCT05488431· Phase 2· Priscilla Hsue, MD· Source

• Active, not recruiting

  Liver Cirrhosis Network Cohort Study

  NCT05740358· Northwestern University· Source

• Recruiting

  Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

  NCT05338697· Yale University· Source

• Active, not recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

  NCT03496883· Phase 3· Joseph Broderick, MD· Source

• Recruiting

  Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

  NCT04722835· University of California, San Francisco· Source

• Recruiting

  Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

  NCT04592445· Axon Therapies, Inc.· Source

• Active, not recruiting

  Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2

  NCT04514861· Profusa, Inc.· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Yale University· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

  NCT04108156· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Biomarkers for Risk Stratification in Lung Cancer

  NCT03774758· University of California, San Francisco· Source

• Active, not recruiting

  Innate Immunity in Ozone-induced Airway Inflammation in COPD

  NCT04669743· University of California, San Francisco· Source

• Active, not recruiting

  Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

  NCT02656511· Phase 4· University of California, San Francisco· Source

• Recruiting

  The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  NCT01202305· University of California, San Francisco· Source

• Recruiting

  The Use of Leukapheresis to Support HIV Pathogenesis Studies

  NCT01161199· University of California, San Francisco· Source

• Recruiting

  SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

  NCT00187512· University of California, San Francisco· Source

• Recruiting

  Collection of Blood for Multiple Collaborative Studies

  NCT01336855· University of California, San Francisco· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV5 recruiting
• Stroke4 recruiting
• Atrial fibrillation1 recruiting
• Coronary artery disease1 recruiting
• Diabetic eye disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• Liver cirrhosis1 recruiting
• Lung cancer1 recruiting
• Smoking and nicotine dependence1 recruiting

Closed trials

• Completed

  An App-based Instructional Platform to Improve Eye Drop Recall

  NCT06045390· University of California, San Francisco· Source

• Completed

  Incomplete Cervical SCI Without Instability

  NCT05653206· AO Foundation, AO Spine· Source

• Completed

  Effect of Rapid Rollover on Pneumothorax After CT-Guided Lung Biopsy

  NCT05342675· University of California, San Francisco· Source

• Withdrawn

  Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

  NCT02229175· Phase 2/3· University of California, San Francisco· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Washington University School of Medicine· Source

• Completed

  Determining Normal Range for Free Light Chains in Serum Among Twins

  NCT04191057· University of California, San Francisco· Source

• Completed

  Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

  NCT03207945· Phase 3· University of California, San Francisco· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Opioid use disorder10 works · 0 trials